Fernando Escalante
Impact in
- Hematology top 5%
- Multiple Myeloma Research and Treatments
- Platelet Disorders and Treatments
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research
Papers in
- Hematology 24
- Multiple Myeloma Research and Treatments 22
-
- Amyloidosis: Diagnosis, Treatment, Outcomes 6
- Protein Degradation and Inhibitors 4
- Co-authors
- Ramón García‐Sánz (18 shared papers)Enrique M. Ocio (10 shared papers)Jesús F. San Miguel (8 shared papers)Norma C. Gutiérrez (12 shared papers)Bruno Paiva (4 shared papers)Rocío Corral (4 shared papers)María‐Victoria Mateos (13 shared papers)María Eugenia Sarasquete (6 shared papers)
- Journals
- Blood (11 papers)Cancers (3 papers)Leukemia (3 papers)Journal of Clinical Oncology (2 papers)HemaSphere (2 papers)
- Partner nations
- SpainUnited StatesUnited Kingdom
In The Last Decade
Fernando Escalante
35 papers receiving 558 citations
Peers
Comparison fields: 5 of 37
- Hematology 297
- Genetics 276
- Pathology and Forensic Medicine 184
- Immunology 117
- Oncology 107
Countries citing papers authored by Fernando Escalante
This map shows the geographic impact of Fernando Escalante's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando Escalante with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando Escalante more than expected).
Fields of papers citing papers by Fernando Escalante
This network shows the impact of papers produced by Fernando Escalante. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando Escalante. The network helps show where Fernando Escalante may publish in the future.
Co-authors
The 25 scholars most cited alongside Fernando Escalante, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 172 | |
| 2 | 2013 | 58 | |
| 3 | 2013 | 47 | |
| 4 | 2014 | 46 | |
| 5 | 2023 | 41 | |
| 6 | 2017 | 28 | |
| 7 | 2020 | 25 | |
| 8 | 2015 | 25 | |
| 9 | 2018 | 17 | |
| 10 | 2016 | 15 | |
| 11 | 2023 | 10 | |
| 12 | 2023 | 10 | |
| 13 | 2011 | 9 | |
| 14 | 2017 | 7 | |
| 15 | 2005 | 6 | |
| 16 | 2022 | 6 | |
| 17 | 2022 | 6 | |
| 18 | 2014 | 4 | |
| 19 | 2019 | 4 | |
| 20 | 2021 | 4 |
About Fernando Escalante
Fernando Escalante is a scholar working on Hematology, Molecular Biology, Genetics, Oncology and Pathology and Forensic Medicine, having authored 38 papers that have together received 569 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (22 papers), Peptidase Inhibition and Analysis (8 papers), Chronic Lymphocytic Leukemia Research (8 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (6 papers), Lymphoma Diagnosis and Treatment (6 papers), Protein Degradation and Inhibitors (4 papers), Advanced Breast Cancer Therapies (3 papers) and Cancer Treatment and Pharmacology (2 papers). The work is most often cited by research in Hematology (297 citations), Genetics (276 citations), Pathology and Forensic Medicine (184 citations), Immunology (117 citations) and Oncology (107 citations). Fernando Escalante has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include Ramón García‐Sánz, Enrique M. Ocio, Jesús F. San Miguel, Norma C. Gutiérrez, Bruno Paiva, Rocío Corral, María‐Victoria Mateos, María Eugenia Sarasquete, Carmen Aguilera and Luis Marı́n. Their work appears in journals such as Blood, Cancers, Leukemia, Journal of Clinical Oncology and HemaSphere.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.